Raltegravir-associated perihepatitis and peritonitis: a single case report.

摘要

Raltegravir, the first approved HIV integrase inhibitor, has demonstrated an excellent safety and tolerability profile in several clinical trials [1] and is currently used widely as one of the key components of salvage regimens. However, the duration of clinical use is relatively short, and unknown adverse effect may occur. Here, we report one case of peritonitis associated with use of raltegravir. Abdominal symptoms appeared within 2 weeks of commencement of treatment, and raltegravir had to be stopped due to worsening of clinical condition.